Cargando…

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes

The a priori risk for infections in patients with myelodysplastic syndromes (MDS) is unknown. This study examines prescription rates of anti‐infective agents in MDS patients before and after diagnosis, in both in‐ and outpatient settings, to provide information on infection management in clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rozema, Johanne, Hoogendoorn, Mels, Potma, Iris, ten Seldam, Inge, Veeger, Nic J. G. M., Kibbelaar, Robby E., van de Loosdrecht, Arjan A., van Roon, Eric N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Haematologic Malignancy ‐ Myeloid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422012/ https://www.ncbi.nlm.nih.gov/pubmed/36051088 http://dx.doi.org/10.1002/jha2.422

Ejemplares similares

Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study
por: Rozema, Johanne, et al.
Publicado: (2022)

Patterns of transfusion burden in an unselected population of patients with myelodysplastic syndromes: A population‐based study
por: Rozema, Johanne, et al.
Publicado: (2021)

Predictors of vascular disease in myelodysplastic syndromes
por: Faber, Mark G., et al.
Publicado: (2020)

Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients
por: Wang, Yu‐Hung, et al.
Publicado: (2022)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
por: Patel, Shyam A., et al.
Publicado: (2023)

Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2022)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

Increased body mass index is a risk factor for acute promyelocytic leukemia
por: Kashanian, Sarah M., et al.
Publicado: (2021)

Models of care for chronic myeloid leukemia patients during the COVID‐19 pandemic in the United Kingdom: Changes in patient attitudes to remote consultations and future implications
por: Duncan, Nicholas, et al.
Publicado: (2021)

DNA methylation analysis improves the prognostication of acute myeloid leukemia
por: Samimi, Hanie, et al.
Publicado: (2021)

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers
por: Hernlund, Emma, et al.
Publicado: (2021)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Diagnostic and molecular testing patterns in patients with newly diagnosed acute myeloid leukemia in the Connect(®) MDS/AML Disease Registry
por: Pollyea, Daniel A., et al.
Publicado: (2020)

The different predictive effects of the intensity and proportion of CD20 expression on the prognosis of B‐lineage acute lymphocyte leukemia
por: Tian, Yun, et al.
Publicado: (2022)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
por: Ishida, Hisashi, et al.
Publicado: (2020)

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies
por: How, Joan, et al.
Publicado: (2022)

Single cell proteogenomic sequencing identifies a relapse‐fated AML subclone carrying FLT3‐ITD with CN‐LOH at chr13q
por: Kim, TaeHyung, et al.
Publicado: (2022)

Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada
por: Cressman, Sonya, et al.
Publicado: (2020)

Fatal renal diseases among patients with hematological malignancies: A population‐based study
por: Li, Sen, et al.
Publicado: (2020)

Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
por: Galiègue‐Zouitina, Sylvie, et al.
Publicado: (2021)

PD1 expression on bone marrow T‐cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy
por: Bassiouny, Noha, et al.
Publicado: (2020)

Longitudinal trends of peripheral blood counts in polycythaemia vera and essential thrombocythemia patients in the UK
por: Carpenter, Lewis, et al.
Publicado: (2022)

Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
por: Symeonidou, Vasiliki, et al.
Publicado: (2022)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China
por: Luo, Jie, et al.
Publicado: (2022)

Molecular characteristics and outcomes in Hispanic and non‐Hispanic patients with acute myeloid leukemia
por: Bradley, Terrence, et al.
Publicado: (2022)

Germline RUNX1 variants in paediatric patients in a French specialised centre
por: Liu, Cécile, et al.
Publicado: (2022)

GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance
por: Inase, Aki, et al.
Publicado: (2022)

Acute leukemias in pregnant women: Results of a retrospective study at a local tertiary‐care hospital in Japan
por: Kobayashi, Shuhei, et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
por: Ayala, Rosa, et al.
Publicado: (2023)

Prophylaxis with low dose tranexamic acid in acute myeloid leukemia patients undergoing intensive chemotherapy
por: Bønløkke, Søren Thorgaard, et al.
Publicado: (2023)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
por: Doorduijn, Jeanette K., et al.
Publicado: (2020)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
por: Xu, Jinglan, et al.
Publicado: (2008)

Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome
por: Toft‐Petersen, Marie, et al.
Publicado: (2016)

Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis
por: Park, Sophie, et al.
Publicado: (2016)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oc441r365695lel0ep1pvfa0au